An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) announced that Chief Executive Officer John Climaco will present at the Virtual Investor Lunch Break event, discussing the company's business outlook and the CNSP opportunity. Interested parties can submit questions live during the event, with a webcast available on the company's website for later viewing.
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ha annunciato che l'Amministratore Delegato John Climaco presenterà durante l'evento Virtual Investor Lunch Break, discutendo le prospettive aziendali e le opportunità CNSP. Gli interessati possono inviare domande in diretta durante l'evento, con una trasmissione web disponibile sul sito web dell'azienda per la visione successiva.
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) anunció que su Director Ejecutivo, John Climaco, presentará en el evento Virtual Investor Lunch Break, discutiendo las perspectivas de negocio de la empresa y la oportunidad CNSP. Los interesados pueden enviar preguntas en vivo durante el evento, con una transmisión web disponible en el sitio web de la compañía para ver más tarde.
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP)는 최고경영자(CEO)인 John Climaco가 'Virtual Investor Lunch Break' 이벤트에서 발표할 것이라고 발표했습니다. 이 발표에서는 회사의 사업 전망과 CNSP 기회에 대해 논의할 예정입니다. 관심 있는 당사자들은 이벤트 도중 실시간으로 질문을 제출할 수 있으며, 회사 웹사이트에서 나중에 웹캐스트를 볼 수 있습니다.
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) a annoncé que le Directeur Général John Climaco présentera lors de l'événement Virtual Investor Lunch Break, discutant des perspectives d'affaires de l'entreprise et des opportunités CNSP. Les parties intéressées pourront soumettre des questions en direct pendant l'événement, avec une webdiffusion disponible sur le site web de l'entreprise pour visionnage ultérieur.
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) gab bekannt, dass der Chief Executive Officer John Climaco auf dem Virtual Investor Lunch Break Event präsentieren wird, wo er die Geschäftsaussichten und die Chancen von CNSP erörtern wird. Interessierte Teilnehmer können während der Veranstaltung live Fragen einreichen, eine Webübertragung wird auf der Website des Unternehmens für spätere Ansicht verfügbar sein.
Positive
None.
Negative
None.
Live video webcast with Chief Executive Officer, John Climaco, on Tuesday, April 23rd at 12:00 PM ET
As part of the event, Mr. Climaco will provide a corporate overview, business outlook and discuss the CNS opportunity. Additionally, interested parties will have the opportunity to submit questions live during the event. Mr. Climaco will answer as many questions as possible.
A live video webcast of the presentation will be available on the Events page of the Investors section of the Company's website (cnspharma.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.
cns pharmaceuticals, inc., a biopharmaceutical company, engages in the development of anti-cancer drug candidates for primary and metastatic cancers of the brain and central nervous system. the company's lead drug candidate is berubicin, which completed phase i clinical trial that is used for the treatment of glioblastoma multiforme. it has license agreements with houston pharmaceuticals, inc. and the university of texas m.d. anderson cancer center; and a development agreement with wpd pharmaceuticals inc. cns pharmaceuticals, inc. was founded in 2017 and is based in houston, texas.
